BDX · Becton, Dickinson and Company

Becton, Dickinson and Company's appointment of Vitor Roque as permanent CFO effective May 7, 2026, confirms internal leadership continuity after his interim tenure starting December 5, 2025. With over 25 years at BD, Roque's deep institutional knowledge spans finance, operations, manufacturing, and global regions, positioning him to drive the New BD strategy, including the accelerated separation of the Biosciences & Diagnostic Solutions business. CEO Tom Polen emphasized Roque's ability to translate strategy into performance and ensure financial discipline at scale. Compensation includes a competitive $770,000 base salary, 95% target bonus, and $3M equity target, plus $500,000 in one-time awards recognizing his interim service. Standard executive benefits and a change-of-control agreement align with peers, signaling stability in the critical CFO role amid BD's focus on growth, execution, and shareholder value in medical technology.